Search

Your search keyword '"ROBERT PETRELLA"' showing total 7 results
Start Over Author "ROBERT PETRELLA" Publication Year Range Last 3 years
7 results on '"ROBERT PETRELLA"'

1. Randomised pilot study comparing a coach to SMARTPhone reminders to aid the management of heart failure (HF) patients: humans or machines

Author

Merrick Zwarenstein, Cheryl Forchuk, Robert Petrella, James Calvin, and Rahel Eynan

Subjects
Medicine (General), R5-920
Abstract

Ambulatory management of congestive heart failure (HF) continues to be a challenging clinical problem. Recent studies have focused on the role of HF clinics, nurse practitioners and disease management programmes to reduce HF readmissions. This pilot study is a pragmatic factorial study comparing a coach intervention, a SMARTPHONE REMINDER system intervention and BOTH interventions combined to Treatment as USUAL (TAU). We determined that both modalities were acceptable to patients prior to randomisation. Fifty-four patients were randomised to the four groups. The COACH group had no readmissions for HF 6 months after enrolment compared with 18% for the SMARTPHONE REMINDER Group, 8% for the BOTH intervention group and 13% for TAU. Medium-to-high medication adherence was maintained in all four groups although sodium consumption was lower at 3 months for the COACH and combined (BOTH) groups. This pilot study suggests a beneficial effect on rehospitalisation with the use of support measures including coaches and telephone reminders that needs confirmation in a larger trial.

Published
2024
Full Text
View/download PDF

2. The ‘miracle cure’: how do primary care physicians prescribe physical activity with the aim of improving clinical outcomes of chronic disease? A scoping review

Author

Robert Petrella, Moira Stewart, Taniya Nagpal, Kristen Reilly, and Jane Thornton

Subjects
Medicine (General), R5-920
Abstract

Objectives To identify how primary care physicians (PCPs) prescribe physical activity for patients with chronic disease, and to determine characteristics of physical activity interventions with improved clinical outcomes of chronic disease.Design A scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews 2018 was completed.Data sources Four bibliographic databases (Medline, EMBASE, SPORTDiscus, CINAHL) and four grey literature/unpublished databases (Proquest, National Institute for Health and Care Excellence, Canadian Health Research Collections, Clinical Trials) were searched from inception to 7 March 2022.Eligibility criteria for selecting studies Studies involving PCP-delivered physical activity prescriptions or counselling for participants with a chronic disease or mental health condition, which reported clinical outcomes were included. Opinion papers, news and magazine articles and case reports were excluded, as were studies in which a physical activity intervention was provided for primary prevention of chronic disease, prescribed by healthcare providers or researchers other than PCPs, or for healthy participants without chronic disease.Results An initial search identified 4992 records. Fifteen studies met inclusion criteria. Characteristics of physical activity prescriptions that improved clinical outcomes included: personalised advice; brief intervention; behavioural supports (handouts and/or referrals) and physician follow-up. Reported adverse events were rare. Research gaps include optimal timing and length of follow-up, and the long-term and cost-effectiveness of interventions.Summary/Conclusion Several characteristics of physical activity counselling by PCPs for patients with chronic disease may improve clinical outcomes, although research gaps remain. Studies exploring the effectiveness of physical activity prescription for individuals with chronic conditions are urgently needed.

Published
2022
Full Text
View/download PDF

3. Safety and pharmacokinetics of EP-104IAR (sustained-release fluticasone propionate) in knee osteoarthritis: A randomized, double-blind, placebo-controlled phase 1 trial

Author

Amanda Malone, James Price, Nicola Price, Vik Peck, Alan Getgood, Robert Petrella, and James Helliwell

Subjects
EP-104IAR, Knee osteoarthritis, Intra-articular, Corticosteroid, Fluticasone propionate, Randomized controlled trial, Diseases of the musculoskeletal system, RC925-935
Abstract

Objective: EP-104IAR is a novel, sustained-release, intra-articular (IA) formulation of the corticosteroid fluticasone propionate (FP), in development for the treatment of osteoarthritis (OA) pain. This study evaluated the safety, pharmacokinetics (PK) and efficacy of a single dose of EP-104IAR in patients with OA of the knee. Design: This was a multi-center, randomized, double-blind, placebo-controlled trial performed at 3 sites in Canada. Subjects with moderate to severe pain received either a single dose of the investigational product EP-104IAR (15 ​mg) or placebo (vehicle) and were evaluated for up to 42 weeks. The primary outcome measures were safety and PK. The study was not powered to assess efficacy, however patient reported outcome measures were analyzed to evaluate pain and symptom relief. Results: Thirty-two subjects were randomized (21 women, 11 men, mean age: 64.8 years). EP-104IAR was well tolerated. Average serum cortisol levels showed no clinically significant deviations compared to placebo and remained within the normal range of cortisol variation. Plasma PK concentrations were within acceptable safety margins, compared to marketed FP products. Synovial fluid FP levels were approximately 2 orders of magnitude higher and at efficacious concentrations for most subjects. Efficacy evaluations indicated that EP-104IAR provided an immediate improvement of OA symptoms and these effects persisted for 8–12 weeks consistently across all measures. Conclusions: This study provides evidence that 15 ​mg of EP-104IAR is well tolerated and has the potential for efficacy in OA patients. These data support further examination of EP-104IAR in larger clinical studies.

Published
2021
Full Text
View/download PDF

4. The 'miracle cure': how do primary care physicians prescribe physical activity with the aim of improving clinical outcomes of chronic disease? A scoping review

Author

Jane Thornton, Taniya Nagpal, Kristen Reilly, Moira Stewart, and Robert Petrella

Subjects
Physical Therapy, Sports Therapy and Rehabilitation, Orthopedics and Sports Medicine
Abstract

ObjectivesTo identify how primary care physicians (PCPs) prescribe physical activity for patients with chronic disease, and to determine characteristics of physical activity interventions with improved clinical outcomes of chronic disease.DesignA scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews 2018 was completed.Data sourcesFour bibliographic databases (Medline, EMBASE, SPORTDiscus, CINAHL) and four grey literature/unpublished databases (Proquest, National Institute for Health and Care Excellence, Canadian Health Research Collections, Clinical Trials) were searched from inception to 7 March 2022.Eligibility criteria for selecting studiesStudies involving PCP-delivered physical activity prescriptions or counselling for participants with a chronic disease or mental health condition, which reported clinical outcomes were included. Opinion papers, news and magazine articles and case reports were excluded, as were studies in which a physical activity intervention was provided for primary prevention of chronic disease, prescribed by healthcare providers or researchers other than PCPs, or for healthy participants without chronic disease.ResultsAn initial search identified 4992 records. Fifteen studies met inclusion criteria. Characteristics of physical activity prescriptions that improved clinical outcomes included: personalised advice; brief intervention; behavioural supports (handouts and/or referrals) and physician follow-up. Reported adverse events were rare. Research gaps include optimal timing and length of follow-up, and the long-term and cost-effectiveness of interventions.Summary/ConclusionSeveral characteristics of physical activity counselling by PCPs for patients with chronic disease may improve clinical outcomes, although research gaps remain. Studies exploring the effectiveness of physical activity prescription for individuals with chronic conditions are urgently needed.

Published
2022

5. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

Author

Sarowar Muhammad Golam, Christer Janson, Richard Beasley, J Mark FitzGerald, Tim Harrison, Bradley Chipps, Rod Hughes, Hana Müllerová, José María Olaguibel, Eleni Rapsomaniki, Helen K. Reddel, Mohsen Sadatsafavi, Gabriel Benhabib, Piushkumar Mandhane, Xavier Bocca Ruiz, Andrew McIvor, Ricardo del Olmo, Bonavuth Pek, Raul Eduardo Lisanti, Robert Petrella, Gustavo Marino, Daniel Stollery, Walter Mattarucco, Meihua Chen, Juan Nogueira, Yan Chen, Maria Parody, Wei Gu, Pablo Pascale, Kim Ming Christopher Hui, Pablo Rodriguez, Manxiang Li, Damian Silva, Shiyue Li, Graciela Svetliza, Lijun Ma, Carlos F. Victorio, Guangyue Qin, Roxana Willigs Rolon, Weidong Song, Anahi Yañez, Wei Tan, Stuart Baines, Yijun Tang, Simon Bowler, Chen Wang, Peter Bremner, Tan Wang, Sheetal Bull, Fuqiang Wen, Patrick Carroll, Feng Wu, Mariam Chaalan, PingChao Xiang, Claude Farah, Zuke Xiao, Gary Hammerschlag, Shengdao Xiong, Kerry Hancock, Jinghua Yang, Zinta Harrington, Jingping Yang, Gregory Katsoulotos, Caiqing Zhang, Joshua Kim, Min Zhang, David Langton, Ping Zhang, Donald Lee, Wei Zhang, Matthew Peters, Xiaohe Zheng, Lakshman Prassad, Dan Zhu, Helen Reddel, Fabio Bolivar Grimaldos, Dimitar Sajkov, Alejandra Cañas Arboleda, Francis Santiago, Carlos Matiz Bueno, Frederick Graham Simpson, Dora Molina de Salazar, Sze Tai, Elisabeth Bendstrup, Paul Thomas, Ole Hilberg, Peter Wark, Carsten Kjellerup, José Eduardo Delfini Cançado, Ulla Weinreich, Thúlio Cunha, Philippe Bonniaud, Marina Lima, Olivier Brun, Alexandre Pinto Cardoso, Pierre-Régis Burgel, Marcelo Rabahi, Christos Chouaid, Syed Anees, Francis Couturaud, John Bertley, Jacques de Blic, Alan Bell, Didier Debieuvre, Amarjit Cheema, Dominique Delsart, Guy Chouinard, Axelle Demaegdt, Michael Csanadi, Pascal Demoly, Anil Dhar, Antoine Deschildre, Ripple Dhillon, Gilles Devouassoux, J. Mark FitzGerald, Carole Egron, David Kanawaty, Lionel Falchero, Allan Kelly, François Goupil, William Killorn, Romain Kessler, Daniel Landry, Pascal Le Roux, Robert Luton, Pascal Mabire, Guillaume Mahay, Yumiko Ide, Stéphanie Martinez, Minehiko Inomata, Boris Melloni, Hiromasa Inoue, Laurent Moreau, Koji Inoue, Chantal Raherison, Sumito Inoue, Emilie Riviere, Motokazu Kato, Pauline Roux-Claudé, Masayuki Kawasaki, Michel Soulier, Tomotaka Kawayama, Guillaume Vignal, Toshiyuki Kita, Azzedine Yaici, Kanako Kobayashi, Sven Philip Aries, Hiroshi Koto, Robert Bals, Koichi Nishi, Ekkehard Beck, Junpei Saito, Andreas Deimling, Yasuo Shimizu, Jan Feimer, Toshihiro Shirai, Vera Grimm-Sachs, Naruhiko Sugihara, Gesine Groth, Ken-ichi Takahashi, Felix Herth, Hiroyuki Tashimo, Gerhard Hoheisel, Keisuke Tomii, Frank Kanniess, Takashi Yamada, Thomas Lienert, Masaru Yanai, Silke Mronga, Ruth Cerino Javier, Jörg Reinhardt, Alfredo Domínguez Peregrina, Christian Schlenska, Marco Fernández Corzo, Christoph Stolpe, Efraín Montano Gonzalez, Ishak Teber, Alejandra Ramírez-Venegas, Hartmut Timmermann, Adrian Rendon, Thomas Ulrich, Willem Boersma, Peter Velling, R.S. Djamin, Sabina Wehgartner-Winkler, Michiel Eijsvogel, Juergen Welling, Frits Franssen, Ernst-Joachim Winkelmann, Martijn Goosens, Carlo Barbetta, Lidwien Graat-Verboom, Fulvio Braido, Johannes in 't Veen, Vittorio Cardaci, Rob Janssen, Enrico Maria Clini, Kim Kuppens, Maria Teresa Costantino, Maarten van den Berge, Giuseppina Cuttitta, Mario van de Ven, Mario di Gioacchino, Ole Petter Brunstad, Alessandro Fois, Gunnar Einvik, Maria Pia Foschino-Barbaro, Kristian Jong Høines, Enrico Gammeri, Alamdar Khusrawi, Riccardo Inchingolo, Torbjorn Oien, Federico Lavorini, Yoon-Seok Chang, Antonio Molino, Young Joo Cho, Eleonora Nucera, Yong Il Hwang, Alberto Papi, Woo Jin Kim, Vincenzo Patella, Young-Il Koh, Alberto Pesci, Byung-Jae Lee, Fabio Ricciardolo, Kwan-Ho Lee, Paola Rogliani, Sang-Pyo Lee, Riccardo Sarzani, Yong Chul Lee, Carlo Vancheri, Seong Yong Lim, Rigoletta Vincenti, Kyung Hun Min, Takeo Endo, Yeon-Mok Oh, Masaki Fujita, Choon-Sik Park, Yu Hara, Hae-Sim Park, Takahiko Horiguchi, Heung-Woo Park, Keita Hosoi, Chin Kook Rhee, Ho Joo Yoon, Alyn Morice, Hyoung-Kyu Yoon, Preeti Pandya, Alvar Agusti García-Navarro, Manish Patel, Rubén Andújar, Kay Roy, Laura Anoro, Ramamurthy Sathyamurthy, María Buendía García, Swaminathan Thiagarajan, Paloma Campo Mozo, Alice Turner, Sergio Campos, Jorgen Vestbo, Francisco Casas Maldonado, Wisia Wedzicha, Manuel Castilla Martínez, Tom Wilkinson, Carolina Cisneros Serrano, Pete Wilson, Lorena Comeche Casanova, Lo’Ay Al-Asadi, Dolores Corbacho, James Anholm, Felix Del Campo Matías, Frank Averill, Jose Echave-Sustaeta, Sandeep Bansal, Gloria Francisco Corral, Alan Baptist, Pedro Gamboa Setién, Colin Campbell, Marta García Clemente, Michael A. Campos, Ignacio García Núñez, Jose García Robaina, Gretchen Crook, Mercedes García Salmones, Samuel DeLeon, Jose Maria Marín Trigo, Alain Eid, Marta Nuñez Fernandez, Ellen Epstein, Sara Nuñez Palomo, Stephen Fritz, José Olaguibel Rivera, Hoadley Harris, Luis Pérez de Llano, Mitzie Hewitt, Ana Pueyo Bastida, Fernando Holguin, Ana Rañó, Golda Hudes, José Rodríguez González-Moro, Richard Jackson, Albert Roger Reig, Alan Kaufman, José Velasco Garrido, David Kaufman, Dan Curiac, Ari Klapholz, Harshavardhan Krishna, Cornelia Lif-Tiberg, Daria Lee, Anders Luts, Robert Lin, Lennart Råhlen, Diego Maselli-Caceres, Stefan Rustscheff, Vinay Mehta, Frances Adams, James N. Moy, Drew Bradman, Ugo Nwokoro, Emma Broughton, Purvi Parikh, John Cosgrove, Sudhir Parikh, Patrick Flood-Page, Frank Perrino, Elizabeth Fuller, James Ruhlmann, Timothy Harrison, Catherine Sassoon, David Hartley, Russell A. Settipane, Keith Hattotuwa, Daniel Sousa, Gareth Jones, Peruvemba Sriram, Keir Lewis, Richard Wachs, Lorcan McGarvey, BioPharmaceuticals R&D [Gothenburg], AstraZeneca, Uppsala University, Malaghan Institute of Medical Research [Wellington, New Zealand], Vancouver Coastal Health Research Institute (VCH), AstraZeneca [Cambridge, UK], Complejo Hospitalario de Navarra, Woolcock Institute of Medical Research [Sydney], The University of Sydney, University of British Columbia (UBC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Médecine de précision par intégration de données et inférence causale (PREMEDICAL), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut Desbrest de santé publique (IDESP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
Pulmonary and Respiratory Medicine, MESH: Humans, MESH: Asthma, Patient-reported measures, Respiratory Medicine and Allergy, Longitudinal studies, MESH: Patient Acceptance of Health Care, Disease burden, Healthcare resource utilisation, Mild asthma, Patient Acceptance of Health Care, Asthma, MESH: Prospective Studies, MESH: Adrenal Cortex Hormones, Adrenal Cortex Hormones, Disease Progression, Humans, Longitudinal Studies, Prospective Studies, MESH: Disease Progression, MESH: Longitudinal Studies, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Lungmedicin och allergi
Abstract

Background: Patients with mild asthma represent a substantial proportion of the population with asthma, yet there are limited data on their true burden of disease. We aimed to describe the clinical and healthcare resource utilisation (HCRU) burden of physician-assessed mild asthma. Methods: Patients with mild asthma were included from the NOVEL observational longiTudinal studY (NOVELTY; NCT02760329), a global, 3-year, real-world prospective study of patients with asthma and/or chronic obstructive pulmonary disease from community practice (specialised and primary care). Diagnosis and severity were based on physician discretion. Clinical burden included physician-reported exacerbations and patient-reported measures. HCRU included inpatient and outpatient visits. Results: Overall, 2004 patients with mild asthma were included; 22.8% experienced >= 1 exacerbation in the previous 12 months, of whom 72.3% experienced >= 1 severe exacerbation. Of 625 exacerbations reported, 48.0% lasted >1 week, 27.7% were preceded by symptomatic worsening lasting >3 days, and 50.1% required oral corticosteroid treatment. Health status was moderately impacted (St George's Respiratory Questionnaire score: 23.5 [standard deviation +/- 17.9]). At baseline, 29.7% of patients had asthma symptoms that were not well controlled or very poorly controlled (Asthma Control Test score = 2 exacerbations in the previous year. In terms of HCRU, at least one unscheduled ambulatory visit for exacerbations was required by 9.5% of patients, including 9.2% requiring >= 1 emergency department visit and 1.1% requiring >= 1 hospital admission. Conclusions: In this global sample representing community practice, a significant proportion of patients with physician-assessed mild asthma had considerable clinical burden and HCRU.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results